Skip to main content

Profiling Responders In Antibody Therapies

Objetivo

"Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an urgent need to develop more potent therapeutic antibodies and to understand the molecular basis for the differential responses of patients to treatment.
This consortium consists of European centres of excellence being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges:
Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.
Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This method is based on the observation that HLA molecules in complex with peptides can be detected in the patient blood and that hundreds of HLA-associated peptides can be sequenced by mass spectrometry. The technology will be used for the profiling of responses following antibody treatment for patients with cancer and rheumatoid arthritis, as well as animal models of transplant rejection. This systems biology approach has the potential to revolutionize patient stratification in very short time.
Finally, patient selection strategies will be investigated using the clinical-grade immunocytokine (F8-IL10) as an example, monitoring antibody uptake at the site of disease by immuno-PET imaging methodologies at VUMC Amsterdam in collaboration with Philogen."

Convocatoria de propuestas

FP7-HEALTH-2012-INNOVATION-1
Consulte otros proyectos de esta convocatoria

Coordinador

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Dirección
Raemistrasse 101
8092 Zuerich
Suiza
Tipo de actividad
Higher or Secondary Education Establishments
Aportación de la UE
€ 539 987
Contacto administrativo
Dario Neri (Prof.)

Participantes (7)

PHILOGEN SPA
Italia
Aportación de la UE
€ 304 980
Dirección
Piazza La Lizza 7
53100 Siena
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Chiara Falciani (Dr.)
PHILOCHEM AG
Suiza
Aportación de la UE
€ 755 028
Dirección
Libernstrasse 3
8112 Otelfingen
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Tim Fugmann (Dr.)
STICHTING VU
Países Bajos
Aportación de la UE
€ 383 034
Dirección
De Boelelaan 1105
1081 HV Amsterdam
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Gerard Hoskens (Dr.)
UNIVERSITATSKLINIKUM JENA
Alemania
Aportación de la UE
€ 286 260
Dirección
Kastanienstr.1
07747 Jena
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Marcus Franz (Dr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Alemania
Aportación de la UE
€ 206 460
Dirección
Geschwister-scholl-platz
72074 Tuebingen
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Claus Garbe (Prof.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Aportación de la UE
€ 285 276
Dirección
Wellington Square University Offices
OX1 2JD Oxford
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Linda Pialek (Ms.)
MEDIZINISCHE UNIVERSITAT GRAZ
Austria
Aportación de la UE
€ 206 460
Dirección
Auenbruggerplatz 2
8036 Graz
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Thomas Korenjak (Mr.)